Skip to content
value.today
MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT
$156 Mmarket cap on Oct 27, 2026-67.2% since Jan 2024
Compare
World rank
#17,164
Revenue
$33 M
For year ending December-2025
Net income
$-45 M
-135.1% margin
SEC filing
Employees
91
As of December 31, 2025
SEC filing

MaxCyte, Inc. in brief

MaxCyte, Inc. is a listed company in the Diagnostics and Research industry, based in Rockville, Maryland, USA. It was founded in 1998. Its market value was $156 M on 27 October 2026, which makes it the 17,164th largest listed company in the world and the 3,290th largest in the USA on this site. In the year to December 2025 it had sales of $33 M and a net loss of $45 M. It employs about 91 people and Maher Masoud is its chief executive. Its largest product and service lines by sales in 2025 were Licenses (37%) and Assay and other service revenue (6%). By market, the largest shares of its 2025 sales came from USA (64%). Its shares trade under the symbol MXCT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About MaxCyte, Inc.

We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation® technology, which is used by biopharmaceutical companies in the complex engineering of a wide variety of cells.

Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.

From the company's annual report filed with the US SEC: read the report

MaxCyte, Inc. timeline

8 events, 1998–2022
  1. 1998
  2. 🏁
    · approximate
    Incorporated as Maxcyte, Inc.
  3. 2004
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2016
  6. 📈
    · approximate
    Listed on London Stock Exchange as MXCT
  7. •
    Legal Entity Identifier issued
    LEI 54930053YHXULRFCU991 registered.
  8. 2021
  9. 📈
    · approximate
    Listed on Nasdaq as MXCT
  10. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 30 July 2021; shares registered for exchange trading on 27 July 2021.
  11. 2022
  12. 💰
    Record revenue of $44 million
    FY2022, the highest of the 7 years on record.
  13. 📍
    Headquarters moved to 9713 Key West Avenue, Rockville

Events of MaxCyte, Inc. from the GLEIF LEI register, SEC EDGAR, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$245 M$490 M$735 M$980 M2023202420252026

World rank over time

▼ down 7,284 places since 2022
2022-01-07: #9922#9,92220222022-12-25: #12253#12,25320222023-07-30: #13229#13,22920232024-01-05: #12903#12,90320242026-03-08: #10249#10,24920262026-08-01: #16393#16,39320262026-10-07: #18384#18,38420262026-10-27: #17206#17,2062026

Rank in USA: #2,632 (Jan 2022) · #2,580 (Dec 2022) · #2,766 (Jul 2023) · #2,582 (Jan 2024) · #1,995 (Mar 2026) · #3,267 (Aug 2026) · #3,438 (Oct 2026) · #3,294 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
4.5×
Price / book
0.9×
Free cash flow yield
-23.2%
Net margin (TTM)
-81.4%
Operating margin
-157.1%
Return on equity
-16.3%
Liabilities / assets
15.3%
Revenue growth
-14.5%
R&D / revenue
63.0%
Revenue per employee
$363 K
Profit per employee
$-490 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue $22M, net income $-13M$22MFY19Fiscal year ending Dec 2020: revenue $26M, net income $-12M$26MFY20Fiscal year ending Dec 2021: revenue $34M, net income $-19M$34MFY21Fiscal year ending Dec 2022: revenue $44M, net income $-24M$44MFY22Fiscal year ending Dec 2023: revenue $41M, net income $-38M$41MFY23Fiscal year ending Dec 2024: revenue $39M, net income $-41M$39MFY24Fiscal year ending Dec 2025: revenue $33M, net income $-45M$33MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$33M-14.5%$-52M$-45M-135.1%
Dec 2024$39M-6.4%$-51M$-41M-106.3%
Dec 2023$41M-6.7%$-48M$-38M-91.8%
Dec 2022$44M+30.6%$-27M$-24M-53.3%
Dec 2021$34M+29.5%$-18M$-19M-56.3%
Dec 2020$26M+21.0%$-11M$-12M-45.2%
Dec 2019$22M—$-12M$-13M-59.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-34M$2M$-36M$-0.42—
Dec 2024$-28M$2M$-29M$-0.39—
Dec 2023$-22M$4M$-25M$-0.37—
Dec 2022$-15M$18M$-33M$-0.23—
Dec 2021$-11M$4M$-15M$-0.21—
Dec 2020$-9M$2M$-11M$-0.17—
Dec 2019$-9M$1M$-10M$-0.23—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$34M
Net income, trailing 12 months
$-28M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $9M, net income $-11M$9MDec ’24Three months to Mar 2025: revenue $10M, net income $-10M$10MMar ’25Three months to Jun 2025: revenue $9M, net income $-12M$9MJun ’25Three months to Sep 2025: revenue $7M, net income $-12M$7MSep ’25Three months to Dec 2025 (from the annual report): revenue $7M, net income $-10M$7MDec ’25Three months to Mar 2026: revenue $10M, net income $-5M$10MMar ’26Three months to Jun 2026: revenue $7M, net income $-9M$7MJun ’26Three months to Sep 2026: revenue $10M, net income $-5M$10MSep ’26

Latest quarter to Sep 2026: revenue $10M (+48.6% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of MaxCyte, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$33 M
Operating income
$-52 M
Net income
$-45 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$203 M
Total liabilities
$31 M
Total equity
$171 M

As of December-2025

Top 100 institutional investors in MaxCyte, Inc.#

As of Sep 30, 2026
119 institutions held 64.8 M shares (about 62.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 37.9%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in MaxCyte, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Capricorn Fund Managers Ltd8,200,0000 (0.00%)7.94%$9 MNov 3, 2026
2Vitruvian Partners LLP5,043,3560 (0.00%)4.88%$6 MNov 13, 2026
3Liontrust Investment Partners LLP4,840,487New4.69%$5 MNov 18, 2026
4Vanguard Capital Management LLC4,008,963-22,321 (-0.55%)3.88%$4 MNov 13, 2026
5Morgan Stanley3,981,178+287,129 (+7.77%)3.86%$4 MNov 13, 2026
6BlackRock, Inc.3,026,506-34,454 (-1.13%)2.93%$3 MNov 13, 2026
7BNP PARIBAS ASSET MANAGEMENT Holding S.A.2,773,5540 (0.00%)2.69%$3 MNov 13, 2026
8Cadian Capital Management, LP2,624,685+423,519 (+19.24%)2.54%$3 MNov 16, 2026
9Two Sigma Investments, LP2,409,859+946,918 (+64.73%)2.33%$3 MNov 16, 2026
10Mudita Advisors LLP2,260,201-1,110,488 (-32.95%)2.19%$3 MNov 16, 2026
11Renaissance Technologies LLC2,035,300+124,500 (+6.52%)1.97%$2 MNov 12, 2026
12Peapod Lane Capital LLC1,980,392-145,360 (-6.84%)1.92%$2 MOct 22, 2026
13RBF Capital, LLC1,625,380+302,937 (+22.91%)1.57%$2 MNov 13, 2026
14Brooklands Fund Management Ltd1,564,570-1,283,513 (-45.07%)1.52%$2 MOct 28, 2026
15Marshall Wace, LLP1,562,275+547,497 (+53.95%)1.51%$2 MNov 13, 2026
16Nano Cap New Millennium Growth Fund L P1,500,000+300,000 (+25.00%)1.45%$2 MNov 13, 2026
17Geode Capital Management, LLC1,249,490-77,424 (-5.83%)1.21%$1 MNov 6, 2026
18Citadel Advisors LLC1,145,207+288,889 (+33.74%)1.11%$1 MNov 16, 2026
19Goldman Sachs Group Inc914,460-327,483 (-26.37%)0.89%$1 MNov 16, 2026
20Gsa Capital Partners LLP890,654+334,710 (+60.21%)0.86%$1 MNov 16, 2026
21Willis Investment Counsel862,7580 (0.00%)0.84%$1 MOct 20, 2026
22Millennium Management LLC689,847-515,074 (-42.75%)0.67%$1 MNov 16, 2026
23Jane Street Group, LLC635,118-927,885 (-59.37%)0.62%$1 MNov 12, 2026
24Vanguard Fiduciary Trust Co610,650-42,553 (-6.51%)0.59%$1 MNov 13, 2026
25Susquehanna International Group, LLP568,553+411,561 (+262.15%)0.55%$1 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in MaxCyte, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26State Street Corp484,150-32,600 (-6.31%)0.47%$1 MNov 12, 2026
27AQR Capital Management LLC452,859-1,429,917 (-75.95%)0.44%$1 MNov 16, 2026
28Arrowstreet Capital, Limited Partnership426,262New0.41%$0 MNov 13, 2026
29Acadian Asset Management LLC415,933New0.40%$0 MNov 9, 2026
30George Kaiser Family Foundation332,418-295,118 (-47.03%)0.32%$0 MNov 16, 2026
31Jacobs Levy Equity Management, Inc313,294+43,029 (+15.92%)0.30%$0 MNov 16, 2026
32Apollo Management Holdings, L.P.307,9870 (0.00%)0.30%$0 MNov 16, 2026
33Vanguard Portfolio Management LLC284,488+24,045 (+9.23%)0.28%$0 MNov 13, 2026
34HSBC Holdings PLC273,819+118,018 (+75.75%)0.27%$0 MNov 16, 2026
35Northern Trust Corp264,432-482 (-0.18%)0.26%$0 MNov 16, 2026
36Dimensional Fund Advisors LP242,131-28,609 (-10.57%)0.23%$0 MNov 4, 2026
37Russell Investments Group, Ltd.237,758+233,787 (+5887.36%)0.23%$0 MNov 6, 2026
38Stonepine Capital Management, LLC224,881-526,725 (-70.08%)0.22%$0 MNov 13, 2026
39Corient Private Wealth LP211,493New0.20%$0 MNov 16, 2026
40Rathbones Group PLC200,8410 (0.00%)0.19%$0 MNov 12, 2026
41UBS Group AG188,683-95,590 (-33.63%)0.18%$0 MNov 10, 2026
42Diametric Capital, LP183,120New0.18%$0 MNov 16, 2026
43Bank Of America Corp /de/181,245+80,529 (+79.96%)0.18%$0 MNov 16, 2026
44Canada Pension Plan Investment Board177,600+141,900 (+397.48%)0.17%$0 MNov 16, 2026
45FMR LLC175,037-5,301 (-2.94%)0.17%$0 MNov 10, 2026
46Barclays PLC147,325-1,688 (-1.13%)0.14%$0 MNov 6, 2026
47Callan Family Office, LLC143,068-11,243 (-7.29%)0.14%$0 MNov 13, 2026
48Squarepoint Ops LLC134,027+119,183 (+802.90%)0.13%$0 MNov 9, 2026
49Graham Capital Management, L.P.120,838New0.12%$0 MNov 16, 2026
50Charles Schwab Investment Management Inc117,1920 (0.00%)0.11%$0 MNov 16, 2026
51Cabot Wealth Management Inc88,6230 (0.00%)0.09%$0 MNov 5, 2026
52Quadrature Capital Ltd84,875-20,641 (-19.56%)0.08%$0 MNov 13, 2026
53BNP Paribas Financial Markets79,655+61,579 (+340.67%)0.08%$0 MNov 12, 2026
54Schonfeld Strategic Advisors LLC79,402New0.08%$0 MNov 16, 2026
55Ameriprise Financial Inc75,804-3,668 (-4.62%)0.07%$0 MNov 16, 2026
56Point72 Asset Management, L.P.68,473-231,380 (-77.16%)0.07%$0 MNov 16, 2026
57Granite Investment Partners, LLC66,315+48,852 (+279.75%)0.06%$0 MNov 4, 2026
58Bridgeway Capital Management, LLC65,168New0.06%$0 MNov 16, 2026
59Mackenzie Financial Corp62,518New0.06%$0 MNov 2, 2026
60Tudor Investment Corp Et Al62,075-16,238 (-20.73%)0.06%$0 MNov 16, 2026
61Vanguard Personalized Indexing Management, LLC61,128-1,864 (-2.96%)0.06%$0 MNov 16, 2026
62Empowered Funds, LLC59,368New0.06%$0 MNov 13, 2026
63Qube Research & Technologies Ltd55,509-333,593 (-85.73%)0.05%$0 MNov 13, 2026
64Waverly Advisors, LLC50,533-3,481 (-6.44%)0.05%$0 MNov 16, 2026
65Catalyst Funds Management Pty Ltd48,113-13,587 (-22.02%)0.05%$0 MNov 12, 2026
66XTX Topco Ltd44,937-161,653 (-78.25%)0.04%$0 MNov 16, 2026
67JMN Financial LLC41,8390 (0.00%)0.04%$0 MNov 10, 2026
68Vanguard Global Advisers, LLC41,0000 (0.00%)0.04%$0 MNov 13, 2026
69Cerity Partners LLC40,245-57,613 (-58.87%)0.04%$0 MNov 13, 2026
70Bank of New York Mellon Corp32,458-47,882 (-59.60%)0.03%$0 MNov 5, 2026
71SEI Investments Co29,700New0.03%$0 MNov 10, 2026
72Kwmg, LLC25,8330 (0.00%)0.03%$0 MOct 7, 2026
73Tower Research Capital LLC (TRC)25,794-28,137 (-52.17%)0.03%$0 MNov 16, 2026
74PNC Financial Services Group, Inc.21,871-1,139 (-4.95%)0.02%$0 MNov 6, 2026
75Stifel Financial Corp20,6280 (0.00%)0.02%$0 MNov 12, 2026
76Mariner, LLC20,463-76,209 (-78.83%)0.02%$0 MNov 12, 2026
77Bolton Securities Corporation19,9580 (0.00%)0.02%$0 MNov 12, 2026
78Man Group plc18,496-430,462 (-95.88%)0.02%$0 MNov 16, 2026
79Spark Investment Management LLC18,100+2,200 (+13.84%)0.02%$0 MNov 13, 2026
80R Squared Ltd16,289-3,491 (-17.65%)0.02%$0 MNov 6, 2026
81Two Sigma Securities, LLC16,276New0.02%$0 MNov 16, 2026
82Prelude Capital Management, LLC13,997New0.01%$0 MNov 16, 2026
83Blair William & Co/il12,500+431 (+3.57%)0.01%$0 MNov 10, 2026
84Axq Capital, LP12,067New0.01%$0 MNov 12, 2026
85Wealth Enhancement Advisory Services, LLC11,626-45,764 (-79.74%)0.01%$0 MOct 13, 2026
86Citigroup Inc11,574+11,120 (+2449.34%)0.01%$0 MNov 4, 2026
87Victory Capital Management Inc10,865-592 (-5.17%)0.01%$0 MNov 10, 2026
88Arax Advisory Partners10,574-20,804 (-66.30%)0.01%$0 MNov 12, 2026
89Jefferies Financial Group Inc.10,000-5,972 (-37.39%)0.01%$0 MNov 5, 2026
90Nuveen, LLC9,047New0.01%$0 MNov 10, 2026
91Diadema Partners LP8,190New0.01%$0 MNov 16, 2026
92Persistent Asset Partners Ltd8,002New0.01%$0 MNov 13, 2026
93Royal Bank Of Canada7,767-417 (-5.10%)0.01%$0 MNov 16, 2026
94Optiver Holding B.V.7,730+7,727 (+257566.67%)0.01%$0 MNov 16, 2026
95GAMMA Investing LLC5,7020 (0.00%)0.01%$0 MOct 8, 2026
96Employees Retirement System of Texas4,270New0.00%$0 MNov 10, 2026
97TrinityBridge Ltd4,0000 (0.00%)0.00%$0 MOct 30, 2026
98Jpmorgan Chase & Co3,798+2,223 (+141.14%)0.00%$0 MNov 12, 2026
99Bare Financial Services, Inc1,5990 (0.00%)0.00%$0 MNov 4, 2026
100Capital Analysts, LLC1,2660 (0.00%)0.00%$0 MNov 13, 2026

All 119 institutional investors, with who bought and sold →

Mutual funds holding MaxCyte, Inc.#

41 funds hold shares worth $9 M (about 7.1% of the company). Since their previous reports 13 added shares and 60 sold, selling $5 M net.
Mutual funds holding MaxCyte, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.74 M$3 M2.7%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.16 M$1 M1.1%<0.01%−0.4%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.518,559$1 M0.50%<0.01%+4.0%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC394,028$0 M0.38%<0.01%−0.8%May 31, 2026
🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc.347,433$0 M0.34%0.15%no changeJun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.301,966$0 M0.29%<0.01%−0.8%May 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC211,975$0 M0.21%0.05%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC199,501$0 M0.19%<0.01%no changeMay 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors164,501$0 M0.16%<0.01%+2.4%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC156,238$0 M0.15%<0.01%+4.7%May 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I144,027$0 M0.14%0.01%no changeMay 31, 2026
🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC109,790$0 M0.11%<0.01%+3.2%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.109,491$0 M0.11%<0.01%+197%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.114,828$0 M0.11%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.77,156$0 M0.07%<0.01%+4.8%May 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors74,409$0 M0.07%<0.01%−23%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC57,279$0 M0.06%<0.01%+35%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC56,050$0 M0.05%<0.01%+19%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.46,791$0 M0.05%<0.01%−37%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC46,473$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS43,428$0 M0.04%0.01%−45%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company40,960$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS37,160$0 M0.04%0.02%−64%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC38,185$0 M0.04%<0.01%−0.3%Jul 31, 2026
🇺🇸 AVIP Fidelity Institutional AM Equity Growth PortfolioCONSTELLATION INVESTMENTS INC22,645$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.22,321$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION20,500$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC18,521$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC18,120$0 M0.02%<0.01%+14%Jul 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.12,450$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.11,457$0 M0.01%<0.01%+1.5%Jul 31, 2026
🇺🇸 Guardian Large Cap Fundamental Growth VIP FundPark Avenue Institutional Advisers LLC7,867$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.7,598$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC6,828$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC5,380$0 M<0.01%<0.01%+115%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC4,758$0 M<0.01%<0.01%+8.6%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC3,837$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC3,722$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC3,760$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC3,354$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC2,235$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 41 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at MaxCyte, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$121 K
1 purchase, 1 insider
Sold, 12 months
$8 K
1 sale, 1 insider
Net, 12 months
$112 K
open market only
Insiders on file
20
since
$489 K-$763 K$0Nov 2023: bought $0 (0 trades), sold $87 K (3 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $763 K (4 trades)Jan 2024: bought $0 (0 trades), sold $26 K (1 trades)Feb 2024: bought $0 (0 trades), sold $23 K (1 trades)FebMar 2024: bought $0 (0 trades), sold $22 K (1 trades)Jun 2024: bought $489 K (2 trades), sold $176 K (2 trades)Jul 2024: bought $0 (0 trades), sold $149 K (3 trades)JulAug 2024: bought $0 (0 trades), sold $161 K (3 trades)Sep 2024: bought $0 (0 trades), sold $203 K (3 trades)Oct 2024: bought $0 (0 trades), sold $190 K (3 trades)OctNov 2024: bought $0 (0 trades), sold $177 K (1 trades)Dec 2024: bought $0 (0 trades), sold $23 K (3 trades)Jan 2025: bought $0 (0 trades), sold $34 K (2 trades)Jan 25Mar 2025: bought $0 (0 trades), sold $27 K (3 trades)Jun 2025: bought $0 (0 trades), sold $22 K (1 trades)Aug 2025: bought $415 K (5 trades), sold $0 (0 trades)AugMar 2026: bought $0 (0 trades), sold $8 K (1 trades)Nov 2026: bought $121 K (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
MaxCyte, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Maher MasoudPresident and CEO, DirectorBuy+100,000$1.208$121 K575,000Form 4
filed John Joseph JohnstonDirectorGrant or award+30,421——201,581Form 4
filed Stanley C. ErckDirectorGrant or award+30,421——428,749Form 4
filed Cynthia CollinsDirectorGrant or award+30,421——111,310Form 4
filed Patrick J. BalthropDirectorGrant or award+30,421——80,998Form 4
filed Rekha HemrajaniDirectorGrant or award+30,421——70,314Form 4
filed Yasir B. Al-WakeelDirectorGrant or award+30,421——80,998Form 4
filed William W. BrookeDirectorGrant or award+30,421——181,300Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: MaxCyte, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.6 M
1.5% of shares · 1.34 days to cover
Buybacks, Q3 2026
$4M
Q3 2026
Shares sold short, last 24 reportsAll stocks →
MaxCyte, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$4M

Fails to deliver

  • : 1 shares at $1.51
  • : 1 shares at $1.43
  • : 1 shares at $1.30
  • : 964 shares at $1.09
  • : 964 shares at $1.08

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

MaxCyte, Inc. scorecard#

Passes 3 of the 20 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 27, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.9×Price to book 0.9× against Diagnostics and Research's median of 3.7×.
    • ✗Price to sales below its peers' median4.5×Price to sales 4.5× against Diagnostics and Research's median of 4.5×.
    • ✗Free cash flow yield above 5%-23.2%Free cash flow is -23.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-14.5%Revenue down 14.5% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-9.3%-9.3% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-9.3%-9.3% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-0.42 vs -0.39Diluted EPS -0.42 in fiscal 2025 against -0.39 the year before (report's currency).
    • ✗Net income higher than five years earlier-$45 M-$45 M in fiscal 2025 against -$12 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$45 MNet income -$45 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-157.1%-157.1% against Diagnostics and Research's median of -2.4% (66 companies).
    • ✗Return on equity above 15%-23.6%-23.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-157.1%-157.1% in fiscal 2025 against -61.8% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities8.3×Current ratio 8.30 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone1.14Z-score 1.14 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.5%Diluted shares up 1.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from MaxCyte, Inc.'s statements, beside the median of Diagnostics and Research.

MaxCyte, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-157.1%-2.4%
Net margin-135.1%-3.6%
Return on equity-23.6%-5.4%
Revenue growth, 3 years a year-9.3%3.6%
Revenue growth-14.5%6.6%
Free cash flow margin-109.5%4.7%

2of 8on the Piotroski tests of financial strength

  • Revenue fell 14.5% against the year before.
  • Net loss of $45 million, the 7th loss-making year in a row.
  • Free cash flow was negative: -$36 million.

MaxCyte, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

MaxCyte, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue33394144r342622
Cost of revenue6.27.14.75.1r3.62.82.5
Gross profit27323739r302319
Research and development21222420r151818
Selling and marketing19272719r138.37.9
General and administrative28303026r197.45.6
Operating expenses79838567r483432
Operating income−52−51−48−27r−18−11−12
Interest and finance income7.310103.9r0.20.10.2
Interest expense and finance costs————0.00.00.1
Other non-operating income (expense)7.310103.8r−0.9−0.8−0.5
Income before tax−45−41−38————
Income tax————000
Net income including minority interests−45−41−38−24r−19−12−13
Net income attributable to shareholders−45−41−38−24r−19−12−13
Earnings per share, basic-0.42-0.39-0.37-0.23-0.21-0.17-0.23
Earnings per share, diluted-0.42-0.39-0.37-0.23-0.21-0.17-0.23
Shares, weighted average (basic)106105103102916956
Shares, weighted average (diluted)106105103102916956
Balance sheet
Cash and cash equivalents20284711r481915
Short-term investments83127122216r20716—
Receivables3.54.75.811r6.95.2—
Inventory7.58.9128.6r5.24.3—
Other current assets4.33.63.93.3r3.31.0—
Current assets118172190252r27045—
Property, plant and equipment18202424r7.74.5—
Right-of-use (leased) assets1111119.9r5.71.7—
Other intangible assets0.7——————
Long-term investments533643————
Total assets203239268287r28452—
Accounts payable1.41.40.70.3r1.80.9—
Current liabilities14161815r1612—
Lease liabilities (non-current)16171816r5.21.2—
Total liabilities31333633r2119—
Retained earnings−261−217−176−138r−114−95—
Shareholders' equity171206232254r263r3314
Total liabilities and equity203239268287r28452—
Shares outstanding10710610410210177—
Cash-flow statement
Depreciation and amortization4.34.34.22.7r1.41.00.6
Share-based compensation9.2131412r8.02.51.8
Cash from operating activities−34−28−22−15r−11−8.8−8.8
Capital expenditure−1.8−1.7−3.7−18r−3.8−2.1−1.3
Acquisitions, net of cash acquired−1.8——————
Cash from investing activities266.955−25r−195−170.5
Shares issued———2.9522912
Cash from financing activities0.72.12.12.9r2352912
Change in cash−7.8−1935−37r293.54.0
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What MaxCyte, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product sales(total)$19 M57%
  • Licenses$12 M37%
  • Assay and other service revenue$2 M6.0%

Business segments

  • Cell Engineering Technology$33 M100%

Countries and regions

  • 🇺🇸 USA$21 M64%
  • Outside the United States(total)$12 M36%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at MaxCyte, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Restructuring 2 · Directors and officers 6 · Material agreement 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 14

MaxCyte, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementUnregistered share saleResults announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Delisting notice8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Results announced8-K
Restructuring8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Restructuring8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 acquisitions, $2 M paid where reported · 2 private funding rounds before listing

Businesses it acquired

Acquisitions by MaxCyte, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
SeQure Inc2025—$2 M100%Annual report

Private share sales · funding history

Private share sales of MaxCyte, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2014$2 MNo. 2Under $2 million21equitySEC
Aug 2009$2 MNo. 1Under $2 million15equity, debtSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at MaxCyte, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $118 K a year.

Certified, FY2026
1
#1,828 among companies on value.today
Worker positions
1
Median wage offered
$118 K
a year, full-time
Applications filed
1
MaxCyte, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Electrical EngineerElectrical Engineers1$118 K

Where: Rockville, MD 1

MaxCyte, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$118 K1
FY202533$135 K3
FY202411$73 K1
FY202311$93 K1
FY202233$106 K3
FY202011$110 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as MaxCyte, Inc.

Layoffs at MaxCyte, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2025
Latest
—
2025-09-22
MaxCyte, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
2024············—
MaxCyte, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
34% of workforceRestructuring planSEC 8-K“The Plan is expected to result in a reduction of approximately 34% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged thro…”Filing
15% of workforceRestructuring planSEC 8-K“The Plan is expected to result in a reduction of approximately 15% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged thro…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How MaxCyte, Inc. compares in Diagnostics and Research

  • Market cap$156 M · higher than 29% of 110
  • Revenue$33 M · higher than 24% of 123
  • Net margin-81.4% · higher than 13% of 112
  • Revenue growth-14.5% · higher than 18% of 89
  • Price / sales4.5× · lower than 44% of 85
  • Price / book0.9× · lower than 84% of 84
  • FCF yield-23.2% · higher than 22% of 66

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
MaxCyte, Inc.🇺🇸$156 M—-81.4%-14.5%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 27, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at MaxCyte, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show MaxCyte, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about MaxCyte, Inc.? Suggest a correction